<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v </plain></SENT>
<SENT sid="1" pm="."><plain>BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18-61) with myeloid or lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> at standard risk (n=10) or high risk of relapse (n=26), who received an allogeneic hematopoietic SCT (HSCT) from HLA-matched related (n=16) or unrelated (n=20) donors </plain></SENT>
<SENT sid="2" pm="."><plain>The source of hematopoietic stem cells was peripheral blood in 28 and marrow in 8 cases </plain></SENT>
<SENT sid="3" pm="."><plain>Rabbit-antithymocyte globulin at 7 mg/kg was utilized in 21 patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD grade II-IV was observed in 19% of the patients (grade III-IV in 14% of patients) and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 11 of 30 evaluable patients (37%) </plain></SENT>
<SENT sid="5" pm="."><plain>At median follow-up of 737 days (range: 152-1,737) for alive patients, overall survival rates in standard- and high-risk patients were 80 and 35%, respectively, and event-free survival rates were 70 and 31%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>TRM was 10% in standard-risk and 19% in high-risk patients </plain></SENT>
<SENT sid="7" pm="."><plain>Post transplant relapse was observed in 20% standard-risk and in 46% high-risk patients </plain></SENT>
<SENT sid="8" pm="."><plain>FluBU conditioning regimen is associated with a limited hematologic and extrahematologic toxicity and with an antitumor activity comparable to other standard myeloablative regimens </plain></SENT>
</text></document>